Patients with lupus nephritis who received hydroxychloroquine demonstrated a significantly lower risk for glomerular ...

A new study published in the journal of Pediatric Nephrology revealed an U-shaped relationship between serum uric acid levels and cardiovascular risk in children with chronic kidney disease ...

Investigators studied IgA nephropathy relapse, its correlation with kidney failure, and risk factors using a prospective cohort.

Statistics, and the standard deviation of our tests, mean that if you order a complete metabolic profile, a lipid panel, a ...

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

The body needs healthy kidneys to perform waste elimination, and chemical equilibrium maintenance. Dr. Yaranov suggests ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...

The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...

GFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for ...

Final results were announced from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan in patients with IgA nephropathy.

Investigators assessed markers of chronic kidney disease (CKD) with cancer risks using data from more than one million patients.